Alternative pathway dysregulation and the conundrum of complement activation by IgG4 immune complexes in membranous nephropathy

Frontiers in Immunology

Volumn 7, Issue APR, 2016, Pages

  Borza, Dorin Bogdan ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

Alternative pathway; Complement; Factor H; Glomerular basement membrane; Heparan sulfate; IgG4; Membranous nephropathy

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ANAPHYLATOXIN; CD59 ANTIGEN; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3C; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; IMMUNOGLOBULIN G4; MANNAN BINDING LECTIN; MEMBRANE COFACTOR PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; OPSONIN; PHOSPHOLIPASE A2 RECEPTOR; PROPERDIN; THROMBOSPONDIN;

ARTICLE; AUTOIMMUNE DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT LECTIN PATHWAY; DISEASE COURSE; GLOMERULUS BASEMENT MEMBRANE; HEYMANN NEPHRITIS; HUMAN; IMMUNE DYSREGULATION; IMMUNOGLOBULIN G4 RELATED DISEASE; IMMUNOREGULATION; INNATE IMMUNITY; MEMBRANOUS GLOMERULONEPHRITIS; NONHUMAN; PHAGOCYTOSIS; PODOCYTE; PROTEINURIA; URINARY EXCRETION;

EID: 84966696740     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00157     Document Type: Article

References (101)

1. Beck LH Jr, Salant DJ. Membranous nephropathy: from models to man. J Clin Invest (2014) 124(6):2307-14. doi: 10.1172/JCI72270
2. Nickolas TL, Radhakrishnan J, Appel GB. Hyperlipidemia and thrombotic complications in patients with membranous nephropathy. Semin Nephrol (2003) 23(4):406-11. doi:10.1016/S0270-9295(03)00058-5
3. Glassock RJ. The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am J Kidney Dis (2010) 56(1):157-67. doi:10.1053/j.ajkd.2010.01.008
4. Nangaku M, Couser WG. Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin Exp Nephrol (2005) 9(3):183-91. doi:10.1007/s10157-005-0357-8
5. Debiec H, Lefeu F, Kemper MJ, Niaudet P, Deschenes G, Remuzzi G, et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med (2011) 364(22):2101-10. doi:10.1056/NEJMoa1013792
6. Farquhar MG, Saito A, Kerjaschki D, Orlando RA. The Heymann nephritis antigenic complex: megalin (gp330) and RAP. J Am Soc Nephrol (1995) 6(1):35-47
7. Debiec H, Guigonis V, Mougenot B, Decobert F, Haymann JP, Bensman A, et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med (2002) 346(26):2053-60. doi:10.1056/NEJMoa012895
8. Debiec H, Nauta J, Coulet F, van der Burg M, Guigonis V, Schurmans T, et al. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet (2004) 364(9441):1252-9. doi:10.1016/S0140-6736(04)17142-0
9. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med (2009) 361(1):11-21. doi:10.1056/NEJMoa0810457
10. Tomas NM, Beck LH Jr, Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med (2014) 371(24):2277-87. doi:10.1056/NEJMoa1409354
11. Prunotto M, Carnevali ML, Candiano G, Murtas C, Bruschi M, Corradini E, et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol (2010) 21(3):507-19. doi:10.1681/ASN.2008121259
12. Murtas C, Bruschi M, Candiano G, Moroni G, Magistroni R, Magnano A, et al. Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin J Am Soc Nephrol (2012) 7(9):1394-400. doi:10.2215/CJN.02170312
13. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol (2014) 5:520. doi:10.3389/fimmu.2014.00520
14. van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martinez-Martinez P, Vermeulen E, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science (2007) 317(5844):1554-7. doi:10.1126/science.1144603
15. van der Zee JS, van Swieten P, Aalberse RC. Inhibition of complement activation by IgG4 antibodies. Clin Exp Immunol (1986) 64(2):415-22
16. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol (2010) 11(9):785-97. doi:10.1038/ni.1923
17. Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol (2007) 171(3):715-27. doi:10.2353/ajpath.2007.070166
18. Thurman JM. Complement in kidney disease: core curriculum 2015. Am J Kidney Dis (2015) 65(1):156-68. doi:10.1053/j.ajkd.2014.06.035
19. Cybulsky AV, Quigg RJ, Salant DJ. Experimental membranous nephropathy redux. Am J Physiol Renal Physiol (2005) 289(4):F660-71. doi:10.1152/ajprenal.00437.2004
20. Cunningham PN, Quigg RJ. Contrasting roles of complement activation and its regulation in membranous nephropathy. J Am Soc Nephrol (2005) 16(5):1214-22. doi:10.1681/ASN.2005010096
21. Segawa Y, Hisano S, Matsushita M, Fujita T, Hirose S, Takeshita M, et al. IgG subclasses and complement pathway in segmental and global membranous nephropathy. Pediatr Nephrol (2010) 25(6):1091-9. doi:10.1007/s00467-009-1439-8
22. Endo M, Fuke Y, Tamano M, Hidaka M, Ohsawa I, Fujita T, et al. Glomerular deposition and urinary excretion of complement factor H in idiopathic membranous nephropathy. Nephron Clin Pract (2004) 97(4):c147-53. doi:10.1159/000079174
23. Doi T, Kanatsu K, Nagai H, Suehiro F, Kuwahara T, Hamashima Y. Demonstration of C3d deposits in membranous nephropathy. Nephron (1984) 37(4):232-5. doi:10.1159/000183255
24. Schulze M, Pruchno CJ, Burns M, Baker PJ, Johnson RJ, Couser WG. Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis. Am J Pathol (1993) 142(1):179-87
25. Brenchley PE, Coupes B, Short CD, O'Donoghue DJ, Ballardie FW, Mallick NP. Urinary C3dg and C5b-9 indicate active immune disease in human membranous nephropathy. Kidney Int (1992) 41(4):933-7. doi:10.1038/ki.1992.143
26. Kon SP, Coupes B, Short CD, Solomon LR, Raftery MJ, Mallick NP, et al. Urinary C5b-9 excretion and clinical course in idiopathic human membranous nephropathy. Kidney Int (1995) 48(6):1953-8. doi:10.1038/ki.1995.496
27. Coupes BM, Kon SP, Brenchley PE, Short CD, Mallick NP. The temporal relationship between urinary C5b-9 and C3dg and clinical parameters in human membranous nephropathy. Nephrol Dial Transplant (1993) 8(5):397-401
28. Salant DJ, Belok S, Madaio MP, Couser WG. A new role for complement in experimental membranous nephropathy in rats. J Clin Invest (1980) 66(6):1339-50. doi:10.1172/JCI109987
29. Baker PJ, Ochi RF, Schulze M, Johnson RJ, Campbell C, Couser WG. Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats. Am J Pathol (1989) 135(1):185-94
30. Cybulsky AV, Rennke HG, Feintzeig ID, Salant DJ. Complement-induced glomerular epithelial cell injury. Role of the membrane attack complex in rat membranous nephropathy. J Clin Invest (1986) 77(4):1096-107. doi:10.1172/JCI112408
31. Nangaku M, Shankland SJ, Couser WG. Cellular response to injury in membranous nephropathy. J Am Soc Nephrol (2005) 16(5):1195-204. doi:10.1681/ASN.2004121098
32. Couser WG. Pathogenesis of glomerular damage in glomerulonephritis. Nephrol Dial Transplant (1998) 13(Suppl 1):10-5. doi:10.1093/ndt/13.suppl_1.10
33. Ronco P, Debiec H. Molecular pathomechanisms of membranous nephropathy: from Heymann nephritis to alloimmunization. J Am Soc Nephrol (2005) 16(5):1205-13. doi:10.1681/ASN.2004121080
34. Vivarelli M, Emma F, Pelle T, Gerken C, Pedicelli S, Diomedi-Camassei F, et al. Genetic homogeneity but IgG subclass-dependent clinical variability of alloimmune membranous nephropathy with anti-neutral endopeptidase antibodies. Kidney Int (2015) 87(3):602-9. doi:10.1038/ki.2014.381
35. Noble B, Van Liew JB, Andres GA, Brentjens JR. Factors influencing susceptibility of LEW rats to Heymann nephritis. Clin Immunol Immunopathol (1984) 30(2):241-54. doi:10.1016/0090-1229(84)90059-X
36. Doi T, Mayumi M, Kanatsu K, Suehiro F, Hamashima Y. Distribution of IgG subclasses in membranous nephropathy. Clin Exp Immunol (1984) 58(1):57-62
37. Jennette JC, Hipp CG. Immunohistopathologic evaluation of C1q in 800 renal biopsy specimens. Am J Clin Pathol (1985) 83(4):415-20. doi:10.1093/ajcp/83.4.415
38. Kanigicherla D, Gummadova J, McKenzie EA, Roberts SA, Harris S, Nikam M, et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int (2013) 83(5):940-8. doi:10.1038/ki.2012.486
39. Hofstra JM, Debiec H, Short CD, Pelle T, Kleta R, Mathieson PW, et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol (2012) 23(10):1735-43. doi:10.1681/ASN.2012030242
40. Debiec H, Hanoy M, Francois A, Guerrot D, Ferlicot S, Johanet C, et al. Recurrent membranous nephropathy in an allograft caused by IgG3kappa targeting the PLA2 receptor. J Am Soc Nephrol (2012) 23(12):1949-54. doi:10.1681/ASN.2012060577
41. Huang CC, Lehman A, Albawardi A, Satoskar A, Brodsky S, Nadasdy G, et al. IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression. Mod Pathol (2013) 26(6):799-805. doi:10.1038/modpathol.2012.237
42. Collins AM, Jackson KJA. Temporal model of human IgE and IgG antibody function. Front Immunol (2013) 4:235. doi:10.3389/fimmu.2013.00235
43. Ma H, Sandor DG, Beck LH Jr. The role of complement in membranous nephropathy. Semin Nephrol (2013) 33(6):531-42. doi:10.1016/j.semnephrol.2013.08.004
44. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med (1995) 1(3):237-43. doi:10.1038/nm0395-237
45. Maverakis E, Kim K, Shimoda M, Gershwin ME, Patel F, Wilken R, et al. Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical review. J Autoimmun (2015) 57:1-13. doi:10.1016/j.jaut.2014.12.002
46. Lhotta K, Wurzner R, Konig P. Glomerular deposition of mannose-binding lectin in human glomerulonephritis. Nephrol Dial Transplant (1999) 14(4):881-6. doi:10.1093/ndt/14.4.881
47. Ma H, Beck LH Jr, Salant DJ. Membranous nephropathy-associated anti-phospholipase A2 receptor IgG4 autoantibodies activate the lectin complement pathway (abstract). J Am Soc Nephrol (2011) 22:62A
48. Harboe M, Ulvund G, Vien L, Fung M, Mollnes TE. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol (2004) 138(3):439-46. doi:10.1111/j.1365-2249.2004.02627.x
49. Hourcade DE. The role of properdin in the assembly of the alternative pathway C3 convertases of complement. J Biol Chem (2006) 281(4):2128-32. doi:10.1074/jbc.M508928200
50. Spitzer D, Mitchell LM, Atkinson JP, Hourcade DE. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J Immunol (2007) 179(4):2600-8. doi:10.4049/jimmunol.179.4.2600
51. Zaferani A, Vives RR, van der Pol P, Hakvoort JJ, Navis GJ, van Goor H, et al. Identification of tubular heparan sulfate as a docking platform for the alternative complement component properdin in proteinuric renal disease. J Biol Chem (2011) 286(7):5359-67. doi:10.1074/jbc.M110.167825
52. Lesher AM, Nilsson B, Song WC. Properdin in complement activation and tissue injury. Mol Immunol (2013) 56(3):191-8. doi:10.1016/j.molimm.2013.06.002
53. Lhotta K, Wurzner R, Rumpelt HJ, Eder P, Mayer G. Membranous nephropathy in a patient with hereditary complete complement C4 deficiency. Nephrol Dial Transplant (2004) 19(4):990-3. doi:10.1093/ndt/gfh008
54. Olaru F, Luo W, Suleiman H, St John PL, Ge L, Mezo AR, et al. Neonatal fc receptor promotes immune complex-mediated glomerular disease. J Am Soc Nephrol (2014) 25(5):918-25. doi:10.1681/ASN.2013050498
55. Zhang JJ, Malekpour M, Luo W, Ge L, Olaru F, Wang XP, et al. Murine membranous nephropathy: immunization with alpha3(IV) collagen fragment induces subepithelial immune complexes and FcgammaR-independent nephrotic syndrome. J Immunol (2012) 188(7):3268-77. doi:10.4049/jimmunol.1103368
56. Luo W, Olaru F, Ge L, Rops AL, Van der Vlag J, Holers VM, et al. Alternative complement pathway is essential for glomerular C3 deposition and progressive proteinuria in murine membranous nephropathy [Abstract FR-OR140]. J Am Soc Nephrol (2012) 23:62A
57. Schiller B, He C, Salant DJ, Lim A, Alexander JJ, Quigg RJ. Inhibition of complement regulation is key to the pathogenesis of active Heymann nephritis. J Exp Med (1998) 188(7):1353-8. doi:10.1084/jem.188.7.1353
58. Quigg RJ, Cybulsky AV, Salant DJ. Effect of nephritogenic antibody on complement regulation in cultured rat glomerular epithelial cells. J Immunol (1991) 147(3):838-45
59. Quigg RJ, Holers VM, Morgan BP, Sneed AE III. Crry and CD59 regulate complement in rat glomerular epithelial cells and are inhibited by the nephritogenic antibody of passive Heymann nephritis. J Immunol (1995) 154(7):3437-43
60. Moll S, Miot S, Sadallah S, Gudat F, Mihatsch MJ, Schifferli JA. No complement receptor 1 stumps on podocytes in human glomerulopathies. Kidney Int (2001) 59(1):160-8. doi:10.1046/j.1523-1755.2001.00476.x
61. Jozsi M, Zipfel PF. Factor H family proteins and human diseases. Trends Immunol (2008) 29(8):380-7. doi:10.1016/j.it.2008.04.008
62. Rodriguez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sanchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol (2004) 41(4):355-67. doi:10.1016/j.molimm.2004.02.005
63. Gordon DL, Kaufman RM, Blackmore TK, Kwong J, Lublin DM. Identification of complement regulatory domains in human factor H. J Immunol (1995) 155(1):348-56
64. Schmidt CQ, Herbert AP, Kavanagh D, Gandy C, Fenton CJ, Blaum BS, et al. A new map of glycosaminoglycan and C3b binding sites on factor H. J Immunol (2008) 181(4):2610-9. doi:10.4049/jimmunol.181.4.2610
65. Langford-Smith A, Keenan TD, Clark SJ, Bishop PN, Day AJ. The role of complement in age-related macular degeneration: heparan sulphate, a ZIP code for complement factor H? J Innate Immun (2014) 6(4):407-16. doi:10.1159/000356513
66. Blaum BS, Hannan JP, Herbert AP, Kavanagh D, Uhrin D, Stehle T. Structural basis for sialic acid-mediated self-recognition by complement factor H. Nat Chem Biol (2015) 11(1):77-82. doi:10.1038/nchembio.1696
67. Pangburn MK. Host recognition and target differentiation by factor H, a regulator of the alternative pathway of complement. Immunopharmacology (2000) 49(1-2):149-57. doi:10.1016/S0162-3109(00)80160-5
68. Meri S, Pangburn MK. Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci U S A (1990) 87(10):3982-6. doi:10.1073/pnas.87.10.3982
69. Kajander T, Lehtinen MJ, Hyvarinen S, Bhattacharjee A, Leung E, Isenman DE, et al. Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc Natl Acad Sci U S A (2011) 108(7):2897-902. doi:10.1073/pnas.1017087108
70. Jozsi M, Oppermann M, Lambris JD, Zipfel PF. The C-terminus of complement factor H is essential for host cell protection. Mol Immunol (2007) 44(10):2697-706. doi:10.1016/j.molimm.2006.12.001
71. Jozsi M, Manuelian T, Heinen S, Oppermann M, Zipfel PF. Attachment of the soluble complement regulator factor H to cell and tissue surfaces: relevance for pathology. Histol Histopathol (2004) 19(1):251-8
72. Ferreira VP, Herbert AP, Hocking HG, Barlow PN, Pangburn MK. Critical role of the C-terminal domains of factor H in regulating complement activation at cell surfaces. J Immunol (2006) 177(9):6308-16. doi:10.4049/jimmunol.177.9.6308
73. Jozsi M, Heinen S, Hartmann A, Ostrowicz CW, Halbich S, Richter H, et al. Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions. J Am Soc Nephrol (2006) 17(1):170-7. doi:10.1681/ASN.2005080868
74. Manuelian T, Hellwage J, Meri S, Caprioli J, Noris M, Heinen S, et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest (2003) 111(8):1181-90. doi:10.1172/JCI16651
75. Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol (2005) 16(2):555-63. doi:10.1681/ASN.2004050380
76. Jozsi M, Strobel S, Dahse HM, Liu WS, Hoyer PF, Oppermann M, et al. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood (2007) 110(5):1516-8. doi:10.1182/blood-2007-02-071472
77. Raats CJ, Bakker MA, Hoch W, Tamboer WP, Groffen AJ, van den Heuvel LP, et al. Differential expression of agrin in renal basement membranes as revealed by domain-specific antibodies. J Biol Chem (1998) 273(28):17832-8. doi:10.1074/jbc.273.28.17832
78. Clark SJ, Ridge LA, Herbert AP, Hakobyan S, Mulloy B, Lennon R, et al. Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycosaminoglycan-binding regions. J Immunol (2013) 190(5):2049-57. doi:10.4049/jimmunol.1201751
79. Kelly U, Yu L, Kumar P, Ding JD, Jiang H, Hageman GS, et al. Heparan sulfate, including that in Bruch's membrane, inhibits the complement alternative pathway: implications for age-related macular degeneration. J Immunol (2010) 185(9):5486-94. doi:10.4049/jimmunol.0903596
80. van den Born J, van den Heuvel LP, Bakker MA, Veerkamp JH, Assmann KJ, Weening JJ, et al. Distribution of GBM heparan sulfate proteoglycan core protein and side chains in human glomerular diseases. Kidney Int (1993) 43(2):454-63. doi:10.1038/ki.1993.67
81. Raats CJ, Luca ME, Bakker MA, Van Der Wal A, Heeringa P, Van Goor H, et al. Reduction in glomerular heparan sulfate correlates with complement deposition and albuminuria in active Heymann nephritis. J Am Soc Nephrol (1999) 10(8):1689-99
82. Levidiotis V, Freeman C, Punler M, Martinello P, Creese B, Ferro V, et al. A synthetic heparanase inhibitor reduces proteinuria in passive Heymann nephritis. J Am Soc Nephrol (2004) 15(11):2882-92. doi:10.1097/01.ASN.0000142426.55612.6D
83. van den Hoven MJ, Rops AL, Vlodavsky I, Levidiotis V, Berden JH, van der Vlag J. Heparanase in glomerular diseases. Kidney Int (2007) 72(5):543-8. doi:10.1038/sj.ki.5002337
84. Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med (1999) 5(7):793-802. doi:10.1038/10518
85. Levidiotis V, Freeman C, Tikellis C, Cooper ME, Power DA. Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis. J Am Soc Nephrol (2004) 15(1):68-78. doi:10.1097/01.ASN.0000103229.25389.40
86. Rops AL, van den Hoven MJ, Veldman BA, Salemink S, Vervoort G, Elving LD, et al. Urinary heparanase activity in patients with Type 1 and Type 2 diabetes. Nephrol Dial Transplant (2012) 27(7):2853-61. doi:10.1093/ndt/gfr732
87. Wiggins RC, Alpers CE, Holzman LB, He JC, Salant DJ, Chugh SS, et al. Glomerular disease: looking beyond pathology. Clin J Am Soc Nephrol (2014) 9(6):1138-40. doi:10.2215/CJN.01450214
88. Chen Y, Schieppati A, Cai G, Chen X, Zamora J, Giuliano GA, et al. Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials. Clin J Am Soc Nephrol (2013) 8(5):787-96. doi:10.2215/CJN.07570712
89. Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol (2011) 22(8):1543-50. doi:10.1681/ASN.2010111125
90. Bomback AS, Derebail VK, McGregor JG, Kshirsagar AV, Falk RJ, Nachman PH. Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol (2009) 4(4):734-44. doi:10.2215/CJN.05231008
91. Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol (2010) 5(12):2188-98. doi:10.2215/CJN.05080610
92. Fervenza FC, Sethi S, Specks U. Idiopathic membranous nephropathy: diagnosis and treatment. Clin J Am Soc Nephrol (2008) 3(3):905-19. doi:10.2215/CJN.04321007
93. Waldman M, Austin HA III. Treatment of idiopathic membranous nephropathy. J Am Soc Nephrol (2012) 23(10):1617-30. doi:10.1681/ASN.2012010058
94. Appel G, Nachman P, Hogas S, Radhakrishnan J, Old C, Hebert L, et al. Eculizumab (C5a complement inhibitor) in the treatment of idiopathic membranous nephropathy [abstract]. J Am Soc Nephrol (2002) 13:668A
95. Pickering MC, Warren J, Rose KL, Carlucci F, Wang Y, Walport MJ, et al. Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc Natl Acad Sci U S A (2006) 103(25):9649-54. doi:10.1073/pnas.0601094103
96. Thurman JM, Kraus DM, Girardi G, Hourcade D, Kang HJ, Royer PA, et al. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol (2005) 42(1):87-97. doi:10.1016/j.molimm.2004.07.043
97. Grossman TR, Hettrick LA, Johnson RB, Hung G, Peralta R, Watt A, et al. Inhibition of the alternative complement pathway by antisense oligonucleotides targeting complement factor B improves lupus nephritis in mice. Immunobiology (2015). doi:10.1016/j.imbio.2015.08.001
98. Holers VM, Rohrer B, Tomlinson S. CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. Adv Exp Med Biol (2013) 735:137-54. doi:10.1007/978-1-4614-4118-2_9
99. Huang Y, Qiao F, Atkinson C, Holers VM, Tomlinson S. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol (2008) 181(11):8068-76. doi:10.4049/jimmunol.181.11.8068
100. Sekine H, Kinser TT, Qiao F, Martinez E, Paulling E, Ruiz P, et al. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum (2011) 63(4):1076-85. doi:10.1002/art.30222
101. Ruseva MM, Peng T, Lasaro MA, Bouchard K, Liu-Chen S, Sun F, et al. Efficacy of targeted complement inhibition in experimental C3 glomerulopathy. J Am Soc Nephrol (2016) 27(2):405-16. doi:10.1681/ASN.2014121195